Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00356772|
Recruitment Status : Completed
First Posted : July 26, 2006
Last Update Posted : July 26, 2006
To evaluate azithromycin ocular conjunctiva concentrations 7 and 14 days after treatment initiation.
To assess ocular and systemic tolerance/safety and azithromycin tear concentrations on Day 7
|Condition or disease||Intervention/treatment||Phase|
|Eye Infections, Bacterial||Drug: Azithromycin||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||Comparison of Azithromycin Level in Tears and in Conjunctiva After Repeated Instillations of T1225 1.5% Eye Drops or After a Single Per Os Administration of Zithromax® (Azithromycin 1g), in 36 Healthy Volunteers|
|Study Start Date :||February 2003|
|Estimated Study Completion Date :||March 2003|
- Azithromycin Ocular Conjunctiva Concentrations on Days 7 and 14.
- Azithromycin Tear Concentrations on Day 7.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00356772
|Principal Investigator:||Claude DUBRAY, Professor||Centre de Pharmacologie Clinique - Clermont-Ferrand (France)|